EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain

EQT Netherlands

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseasesFinancing was co-led by EQT Life Sciences from the LSP Dementia Fund, together with age1 and participation from laso Ventures, and alongside existing investorsInvestment underscores EQT Life Sciences' commitment to high-impact therapeutics and will support Aerska's ambition to address a significant unmet need in neuroscience drug developmentView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-co-leads-usd-39-million-series-a-in-aerska-to-help-systematically-deliver-rna-medicines-to-the-brain-302682574.html